All Releases
View Summary Celldex Reports Third Quarter 2016 Results
Nov 7, 2016
PDF 35.5 KB Add to Briefcase
View Summary Celldex Expands Antibody and Immuno-Oncology Portfolio with the Acquisition of Kolltan Pharmaceuticals
Nov 1, 2016
PDF 21.5 KB Add to Briefcase
View Summary Phase 2 Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory Metastatic Melanoma Meets Primary Overall Response Endpoint and Demonstrates Clinically Meaningful Duration of Response
Oct 9, 2016
PDF 21.1 KB Add to Briefcase
View Summary Celldex Therapeutics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable
Sep 23, 2016
PDF 9.5 KB Add to Briefcase
View Summary Celldex Appoints Elizabeth Crowley as Chief Product Development Officer
Aug 11, 2016
PDF 13.1 KB Add to Briefcase
View Summary Celldex Reports Second Quarter 2016 Results
Aug 8, 2016
PDF 34.9 KB Add to Briefcase
View Summary Celldex to Report Second Quarter 2016 Financial Results and Host Corporate 2016 Objectives Update Call
Aug 2, 2016
PDF 9.9 KB Add to Briefcase
View Summary Celldex Therapeutics Initiates Phase 1/2 Clinical Trial of New Product Candidate CDX-014 in Advanced Renal Cell Carcinoma
Jul 11, 2016
PDF 15.9 KB Add to Briefcase
View Summary Celldex Therapeutics to Participate in the Cantor Fitzgerald 2nd Annual Healthcare Conference
Jul 7, 2016
PDF 9.4 KB Add to Briefcase
View Summary Celldex Therapeutics' CDX‑1401, CDX‑301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma
Jun 4, 2016
PDF 17.7 KB Add to Briefcase
View Summary Celldex Reports First Quarter 2016 Results
May 5, 2016
PDF 35.2 KB Add to Briefcase
View Summary Celldex Therapeutics Initiates Phase 1/2 Study of Glembatumumab Vedotin in Squamous Cell Lung Cancer
Apr 27, 2016
PDF 21.3 KB Add to Briefcase
View Summary Celldex Therapeutics Presents Data Supporting the Clinical Development of Glembatumumab Vedotin and the Preclinical CD40 Program at the AACR Annual Meeting 2016
Apr 20, 2016
PDF 23.1 KB Add to Briefcase
View Summary Celldex Therapeutics Presents Favorable Safety Profile and Immune Response Data from Phase 1/2 Study of Varlilumab and Nivolumab at the AACR Annual Meeting 2016
Apr 18, 2016
PDF 30.5 KB Add to Briefcase
View Summary Celldex Therapeutics to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2016
Mar 17, 2016
PDF 21.9 KB Add to Briefcase
View Summary Data Safety and Monitoring Board Recommends Celldex's Phase 3 Study of RINTEGA® (rindopepimut) in Newly Diagnosed Glioblastoma be Discontinued as it is Unlikely to Meet Primary Overall Survival Endpoint in Patients with Minimal Residual Disease
Mar 7, 2016
PDF 22.1 KB Add to Briefcase
View Summary Celldex Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference
Mar 3, 2016
PDF 17.3 KB Add to Briefcase
View Summary Celldex Reports Fourth Quarter and Year-End 2015 Results
Feb 25, 2016
PDF 44.4 KB Add to Briefcase
View Summary Celldex Presents Preliminary Cohort Data from Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Harvest at the 2016 BMT Tandem Meeting
Feb 20, 2016
PDF 23.4 KB Add to Briefcase
View Summary Celldex to Report Fourth Quarter and Year-End 2015 Business/Financial Results and Host 2016 Corporate Strategy Conference Call
Feb 18, 2016
PDF 18.4 KB Add to Briefcase
Showing 21-40 of 154 Page: 1 2 3 4 5 6 ... 8  Previous 20 | Next 20
Showing 21-40 of 154
Page: 1 2 3 4 5 6 ... 8
 Previous 20 | Next 20
Add to Briefcase = add release to Briefcase